Evidence map›Paper›PMID 42073537›Full record

ArticleCancers2026

The Prognostic Impact of the Ki-67 Proliferation Index in Patients with Surgically Treated Spinal Metastases.

Saif-Eldin Abedellatif, Marija Janjic, Logman Khalafov, Harun Asoglu, Juliane Dittmer, Muriel Heimann, Mohammed Jaber, Haitham Alenezi, Marieta Ioana Toma, Matthias Schneider and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Saif-Eldin AbedellatifDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, Building 81, 53127 Bonn, Germany.
Marija JanjicDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, Building 81, 53127 Bonn, Germany.
Logman KhalafovDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, Building 81, 53127 Bonn, Germany.
Harun AsogluDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, Building 81, 53127 Bonn, Germany.
Juliane DittmerDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, Building 81, 53127 Bonn, Germany.
Muriel HeimannDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, Building 81, 53127 Bonn, Germany.
Mohammed JaberDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, Building 81, 53127 Bonn, Germany.
Haitham AleneziDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, Building 81, 53127 Bonn, Germany.ORCID 0009-0004-0955-9158
Marieta Ioana TomaInstitute of Pathology, University Hospital Bonn, 53127 Bonn, Germany.ORCID 0000-0002-4803-3712
Matthias SchneiderDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, Building 81, 53127 Bonn, Germany.ORCID 0000-0002-6025-7479
Hartmut VatterDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, Building 81, 53127 Bonn, Germany.
Motaz HamedDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, Building 81, 53127 Bonn, Germany.ORCID 0000-0003-4828-7496
Mohammed BanatDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, Building 81, 53127 Bonn, Germany.ORCID 0000-0001-7986-5215

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognostic assessment of patients with spinal metastases is primarily based on clinical and radiological parameters. Biological tumor characteristics such as the proliferation marker Ki-67 have prognostic relevance in various metastatic settings. This study aimed to evaluate the prognostic impact of the Ki-67 proliferation index on survival outcomes in patients undergoing surgery for spinal metastases.

methodsWe included 166 patients who underwent surgical treatment for spinal metastases at our university clinic between 2015 and 2024. Clinical, functional, tumor-related, and perioperative variables were collected. Receiver operating characteristic (ROC) analysis was performed to evaluate the discriminatory ability of Ki-67, and comparisons were made between patient groups according to Ki-67 expression (≤20% vs. >20%).

resultsBased on ROC analysis, Ki-67 demonstrated a moderate but significant predictive ability for 1-year mortality (area under the curve [AUC]: 0.69,

conclusionsThe Ki-67 proliferation index is a significant prognostic biomarker in surgically treated patients with spinal metastases. A Ki-67 index threshold of 20% identifies patients at increased risk of early mortality and significantly reduced overall survival.

Indexed as

biomarkerKi-67 indexoverall survivalspinal metastasissurgical treatment

Identifiers

PMID42073537
PMCPMC13114361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.